title: Caution for interstitial lung disease as a cause of CA 15-3 rise in advanced breast cancer patients treated with everolimus.
authors.affiliation: Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
authors.forename: Annelieke E C A B
authors.initials: AE
authors.lastname: Willemsen
authors.forename: Jan C
authors.initials: JC
authors.lastname: Grutters
authors.forename: Winald R
authors.initials: WR
authors.lastname: Gerritsen
authors.forename: Jolien
authors.initials: J
authors.lastname: Tol
authors.forename: Carla M L
authors.initials: CM
authors.lastname: van Herpen
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000097:blood* / Q000150:complications* / Q000188:drug therapy; D016903:Drug Monitoring / Q000379:methods; D000068338:Everolimus; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000097:blood* / Q000209:etiology*; D018396:Mucin-1 / Q000097:blood* / Q000276:immunology; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D018396:Mucin-1; D000068338:Everolimus; D020123:Sirolimus